投資
2投資退出
1基金
1想告知投資者類似裏奇蒙德兄弟關於你的公司嗎?
提交你的分析師簡報在投資者麵前,CB Insights的平台上的客戶和合作夥伴。188bet游戏
最新的裏奇蒙德兄弟新聞
2023年4月14日
VCPro數據庫2023 26日版-一個可下載的和可搜索的數據庫與風險資本6900 +全球風險資本和私人股本公司。最可靠的、最新的和負擔得起的風險資本的目錄。VCPro數據庫可以在Windows和macOS版本。自1998年以來,它已經出版。BioVentrix®係列融資融資關閉4850萬美元由Andera合作夥伴包括鸕鶿資產管理、Taglich兄弟Inc . Squarepoint首都和裏士滿兄弟支持上市前的批準Revivent TC®係統缺血性心力衰竭患者曼斯菲爾德。,April 13, 2023-- BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process in patients with congestive heart failure, today announced the completion of $48.5 million Series A round financing. The round was led by Andera Partners, a prominent life-science venture capital investor. The investor syndicate also included Cormorant Asset Management, Taglich Brothers Inc., Squarepoint Capital, and Richmond Brothers. In conjunction with the financing, BioVentrix appointed Raphael Wisniewski of Andera Partners and Bihua Chen of Cormorant Asset Management to its Board of Directors. The financing will support completion of the BioVentrix Premarket Approval (PMA) submission for its Revivent TC System, fund expanded access to allow additional procedures following the successful completion of enrollment in its PMA study and initial preparations for commercial launch. BioVentrix recently received approval from the U.S. Food and Drug Administration for an Expanded Access Program following the successful completion of enrollment in ALIVE, a prospective, multi-center, dual-arm pivotal study. The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar who have a suboptimal response to guideline-directed medical therapy. The Revivent TC procedure employs myocardial micro-anchor implants to reconstruct the dilated left ventricle resulting in a more efficient chamber. Jim Dillon, President & CEO of BioVentrix, Inc. said, "Our ability to complete a financing with prominent world class investors and the support of our existing shareholders is a testament to our team and the size of the untapped market opportunity in front of us. Treating advanced heart failure patients through left ventricular restoration is now recognized by the clinical cardiology community as an approach whose time has come." About BioVentrix BioVentrix, Inc. is a privately held medical device company focused on the development of less invasive therapies to treat the failing left ventricle (LV), the most common cause of heart failure. BioVentrix technologies aim to improve cardiac function by directly addressing LV dilation. The Company is preparing to submit the PMA application to the FDA later this year. The BioVentrix and Revivent TC trademarks are registered trademarks of BioVentrix. Revivent TC is currently considered an Investigational Device and limited to investigational use in The United States.
裏士滿兄弟投資
2投資
裏士滿兄弟了2投資。他們最新的投資BioVentrix作為他們的一部分一個係列在2023年4月4日。
裏士滿兄弟投資活動
日期 |
輪 |
公司 |
量 |
新的嗎? |
共同投資者 |
來源 |
---|---|---|---|---|---|---|
4/13/2023 |
一個係列 |
BioVentrix |
48.5美元 |
是的 |
4 |
|
7/22/2019 |
一個係列 |
日期 |
4/13/2023 |
7/22/2019 |
---|---|---|
輪 |
一個係列 |
一個係列 |
公司 |
BioVentrix |
|
量 |
48.5美元 |
|
新的嗎? |
是的 |
|
共同投資者 |
||
來源 |
4 |
裏奇蒙德兄弟投資退出
1投資退出
裏奇蒙德兄弟有1投資組合退出。他們最新的投資退出Ocuphire製藥 在2020年6月18日。
日期 |
退出 |
公司 |
估值
提交的估值公司,采自國家申請或者新聞,由VentureSource的提供,或基於比較數據的估值模型。
|
收購者 |
來源 |
---|---|---|---|---|---|
6/18/2020 |
反向收購 |
3 |
日期 |
6/18/2020 |
---|---|
退出 |
反向收購 |
公司 |
|
估值 |
|
收購者 |
|
來源 |
3 |
裏奇蒙德兄弟基金的曆史
1基金曆史
裏奇蒙德兄弟有1 基金,包括央行機會基金。
截止日期 |
基金 |
基金類型 |
狀態 |
量 |
來源 |
---|---|---|---|---|---|
|
央行機會基金 |
|
|
20.27美元 |
1 |
截止日期 |
|
---|---|
基金 |
央行機會基金 |
基金類型 |
|
狀態 |
|
量 |
20.27美元 |
來源 |
1 |
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。